Microba Life Sciences (ASX:MAP) Cash Payments: A$-34.15 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Microba Life Sciences Cash Payments?

Microba Life Sciences ASX:MAP +2.13% Cash Payments is A$-34.15 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Microba Life Sciences's Cash Payments for the six months ended in Dec. 2025 was A$-16.42 Mil.

Microba Life Sciences's Cash Payments for the trailing twelve months (TTM) ended in Dec. 2025 was A$-34.15 Mil.

Microba Life Sciences Cash Payments Historical Data

* Premium members only.

The historical data trend for Microba Life Sciences's Cash Payments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences Cash Payments Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Cash Payments
-17.84 -22.22 -35.30 -35.78

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Payments Get a 7-Day Free Trial Premium Member Only -15.75 -19.55 -18.06 -17.73 -16.42

Microba Life Sciences Cash Payments Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Payments represents cash flow paid from operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Payments" section for non-financial companies:
Payments to Suppliers for Goods and Services
Payments on Behalf of Employees
Other Cash Payments from Operating Activities

Cash Payments for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-34.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Payments →
What does a Cash Payments of A$-34.15 Mil mean?
Microba Life Sciences (ASX:MAP) has a Cash Payments of A$-34.15 Mil as of Dec. 2025. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for Microba Life Sciences and its competitors.
Is Microba Life Sciences' Cash Payments too high?
Microba Life Sciences' current Cash Payments is A$-34.15 Mil.
How does Microba Life Sciences' Cash Payments compare to TMO and DHR?
Microba Life Sciences' Cash Payments of A$-34.15 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Payments for a Medical Diagnostics & Research company?
A good Cash Payments depends on the Medical Diagnostics & Research industry context. However, Cash Payments should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Payments mean?
A high Cash Payments can signal that a stock is expensive relative to its fundamentals. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for Microba Life Sciences and its competitors. Microba Life Sciences's current Cash Payments is A$-34.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.23, compared to a current price of A$0.05 — trading 79.1% below its estimated fair value. The current Cash Payments is A$-34.15 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Payments calculated?
Cash Payments is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Cash Payments is A$-34.15 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microba Life Sciences Business Description

Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.